TPG Biologics is a biotechnology company that specializes in the early stage research and development of biologics. We have three business scopes: CRO services, biosimilar cell lines, and novel drug development.

Our mission is to be the best partner for worldwide pharmaceutical and biotech companies.

TPG’s CRO services provide customers an integrated solution for developing biologics using our versatile technology. The core components of TPG’s technology platform are Drug Design, Cell Line Development, and Process Development & Analytics. Using these technologies, TPG has collaborated with international biotech and pharmaceutical companies, mainly from Japan, as well as Asia-Pacific, Europe, and the Middle East.. The CRO service business has brought steady income for TPG and has provided a solid financial basis.

In addition to our CRO services, TPG maintains a cell line library for biosimilar monoclonal antibodies. These cell lines have been purchased by major pharmaceutical companies interested in developing biosimilar products.

TPG is now turning our sights to the field of novel drugs, either by in-house development or co-development. Using our platform technology, TPG has begun work on our ECC01 project. ECC01 is a dual-function fusion protein possessing cancer-marker binding ability and a catalytic domain to convert a non-toxic pro-drug to a cytotoxic drug. The ECC01 protein shows good inhibitory effect on tumor growth in animal models. In addition, TPG has signed a collaborative research agreement to develop novel micelle drug. This collaboration combines TPG’s expertise in biologics development and NanoCarrier’s nanoparticle technology to create innovative drug products.

In summary, TPG has extensive expertise in biologics and cell line generation. Over the years, TPG has gained international reputation through our CRO services and biosimilar cell lines. Following this great track records, TPG is now entering the field of novel drugs through both in-house development and collaboration with international companies.